MedTrace Logo

A Study of AK104 (SC) in Combination With Oxaliplatin and Capecitabine (XELOX) Versus AK104 (IV) in Combination With XELOX in Participants With Unresectable Locally Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma

NCT07449780 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 422

Last updated 2026-03-04

No results posted yet for this study

Summary

A Study of AK104 (SC) in Combination With Oxaliplatin and Capecitabine (XELOX) Versus AK104 (IV) in Combination With XELOX in Participants With Unresectable Locally Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma

Conditions

  • Gastric / Gastroesophageal Junction Adenocarcinoma

Interventions

DRUG

AK104(SC)

AK104:subcutaneous injection

DRUG

AK104(IV)

AK104:intravenous

DRUG

Capecitabine

oral

DRUG

Oxaliplatin injection

intravenous

Sponsors & Collaborators

Principal Investigators

  • Yanqiao Zhang · The Second Affiliated Hospital of Harbin Medical University

  • Tao Zhang · UNIVERSITY OF SCIENCE AND TECHNOLOGY UNION HOSPITAL TONG JI MEDICAL COLLEGE HUA ZHONG

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-31
Primary Completion
2027-11-17
Completion
2028-02-15

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07449780 on ClinicalTrials.gov